BioInvent International AB (LTS:0H22) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


LTS:0H22 BioInvent International AB LTS:0H22
48 GF Score
Price kr23.63
GF Value kr50.67
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioInvent International AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0H22 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BioInvent International AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0H22
48GF Score
BioInvent International AB LTS:0H22
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (LTS:0H22) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr23.63 is trading 53.4% below its estimated GF Value™ of kr50.67. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for LTS:0H22:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr50.67 vs. price of kr23.63 (53.4% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Other Exchanges BINV:SwedenBIX:Germany
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
48GF Score

Get the complete analysis for LTS:0H22

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.63
Price
kr50.67
GF Value